MedTrace Logo

Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma

NCT03822936 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-13

No results posted yet for this study

Summary

Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.

Conditions

  • Cancer of Pancreas
  • Pancreas Adenocarcinoma
  • Resectable Pancreatic Cancer

Interventions

DRUG

Preoperative chemotherapy

Preoperative chemotherapy, carbon ion therapy, surgery

RADIATION

Preoperative radiotherapy

Preoperative chemotherapy, carbon ion therapy, surgery

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    collaborator OTHER

  • CNAO National Center of Oncological Hadrontherapy

    lead OTHER

Principal Investigators

  • Francesca Valvo, MD · CNAO National Center of Oncological Hadrontherapy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-08
Primary Completion
2022-08-08
Completion
2025-02-10
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03822936 on ClinicalTrials.gov